Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Endometrial Cancer Resource Center

Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
From Oncology
News
Cost-Effectiveness Analysis of Immunotherapy Regimes in Upfront Treatment With Chemotherapy for Endometrial Cancer
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
News
Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer
02/13/2024

Stephanie Holland 

Stephanie Holland 
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective...
02/13/2024
Oncology
From Oncology
News
Patient-Reported Quality of Life in Patients With Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab
01/17/2024

By Emry Lloyd

By Emry Lloyd
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Researchers have found that a...
01/17/2024
Journal of Clinical Pathways
News
Survival Benefits of Carboplatin Plus Paclitaxel and Immunotherapy in Patients With Advanced Endometrial Cancer
11/29/2023

Grace Taylor

Grace Taylor
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and...
11/29/2023
Journal of Clinical Pathways
Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer: A Real-World Study
11/07/2023

Grace Taylor

Grace Taylor
Keiko Wada, MS, IQVIA Inc, and colleagues analyzed the treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy for patients with endometrial cancer in the US.
Keiko Wada, MS, IQVIA Inc, and colleagues analyzed the treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy for patients with endometrial cancer in the US.
Keiko Wada, MS, IQVIA Inc, and...
11/07/2023
Journal of Clinical Pathways
News
FDA Approves Dostarlimab-gxly With Chemotherapy for Patients With Endometrial Cancer
08/16/2023

Emry Lloyd

Emry Lloyd
In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.
In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.
In July 2023, the FDA approved...
08/16/2023
Journal of Clinical Pathways
News
The Medicaid Expansion’s Impact on Affordable Care: Did it Increase the Number of Patients Receiving Adjuvant Radiation Treatment?
08/02/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a study on the number of patients with endometrial cancer who received adjuvant radiation treatment in the states that implemented further Medicaid expansion.
Researchers conducted a study on the number of patients with endometrial cancer who received adjuvant radiation treatment in the states that implemented further Medicaid expansion.
Researchers conducted a study on...
08/02/2023
Journal of Clinical Pathways
News
Study Analyzes Adjuvant Chemoradiotherapy vs Adjuvant Chemotherapy for Patients with Stage III Endometrial Cancer Following Radical Surgery
04/19/2023

Grace Taylor

Grace Taylor
Si-yu Cao, MD, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Sichuan, China, and colleagues recently compared the effectiveness of adjuvant chemoradiotherapy (ACR) to adjuvant chemotherapy (AC) for...
Si-yu Cao, MD, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Sichuan, China, and colleagues recently compared the effectiveness of adjuvant chemoradiotherapy (ACR) to adjuvant chemotherapy (AC) for...
Si-yu Cao, MD, Department of...
04/19/2023
Journal of Clinical Pathways
News
Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer
04/14/2023
At the 2023 ESMO Gynecological Cancers Congress in Barcelona, Spain, Mansoor Raza Mirza, MD, a clinical oncologist from Rigshospitalet in Denmark, presented data on nonimmunological achievements and the role of HER2, B53, and other molecular...
At the 2023 ESMO Gynecological Cancers Congress in Barcelona, Spain, Mansoor Raza Mirza, MD, a clinical oncologist from Rigshospitalet in Denmark, presented data on nonimmunological achievements and the role of HER2, B53, and other molecular...
At the 2023 ESMO Gynecological...
04/14/2023
Journal of Clinical Pathways
FDA Approves Dostarlimab-Gxly for Patients With dMMR Recurrent or Advanced Endometrial Cancer
03/28/2023

Grace Taylor

Grace Taylor
On February 9, 2023, the FDA granted approval to dostarlimab-gxly for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer.
On February 9, 2023, the FDA granted approval to dostarlimab-gxly for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer.
On February 9, 2023, the FDA...
03/28/2023
Journal of Clinical Pathways

Expert Insights

Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
David Barrington, MD
Videos
Analyzing Treatment Patterns Among Patients With Stage IB Grade 3 Endometrioid Endometrial Carcinoma
04/07/2022
David Barrington, MD, discusses a study that sought to describe national treatment patterns over time and examine associations between treatment modality and overall survival in patients with endometrioid endometrial carcinoma.
David Barrington, MD, discusses a study that sought to describe national treatment patterns over time and examine associations between treatment modality and overall survival in patients with endometrioid endometrial carcinoma.
David Barrington, MD, discusses...
04/07/2022
Journal of Clinical Pathways
David Barrington, MD
Videos
Cost-Effectiveness of Lenvatinib Plus Pembrolizumab for Endometrial Cancer
06/10/2021
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses...
06/10/2021
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways

Newsfeed

News
Cost-Effectiveness Analysis of Immunotherapy Regimes in Upfront Treatment With Chemotherapy for Endometrial Cancer
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
News
Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer
02/13/2024

Stephanie Holland 

Stephanie Holland 
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective...
02/13/2024
Oncology
News
Patient-Reported Quality of Life in Patients With Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab
01/17/2024

By Emry Lloyd

By Emry Lloyd
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Researchers have found that a...
01/17/2024
Journal of Clinical Pathways
News
Survival Benefits of Carboplatin Plus Paclitaxel and Immunotherapy in Patients With Advanced Endometrial Cancer
11/29/2023

Grace Taylor

Grace Taylor
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and...
11/29/2023
Journal of Clinical Pathways
News
FDA Approves Dostarlimab-gxly With Chemotherapy for Patients With Endometrial Cancer
08/16/2023

Emry Lloyd

Emry Lloyd
In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.
In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.
In July 2023, the FDA approved...
08/16/2023
Journal of Clinical Pathways
News
The Medicaid Expansion’s Impact on Affordable Care: Did it Increase the Number of Patients Receiving Adjuvant Radiation Treatment?
08/02/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a study on the number of patients with endometrial cancer who received adjuvant radiation treatment in the states that implemented further Medicaid expansion.
Researchers conducted a study on the number of patients with endometrial cancer who received adjuvant radiation treatment in the states that implemented further Medicaid expansion.
Researchers conducted a study on...
08/02/2023
Journal of Clinical Pathways
News
Study Analyzes Adjuvant Chemoradiotherapy vs Adjuvant Chemotherapy for Patients with Stage III Endometrial Cancer Following Radical Surgery
04/19/2023

Grace Taylor

Grace Taylor
Si-yu Cao, MD, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Sichuan, China, and colleagues recently compared the effectiveness of adjuvant chemoradiotherapy (ACR) to adjuvant chemotherapy (AC) for...
Si-yu Cao, MD, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Sichuan, China, and colleagues recently compared the effectiveness of adjuvant chemoradiotherapy (ACR) to adjuvant chemotherapy (AC) for...
Si-yu Cao, MD, Department of...
04/19/2023
Journal of Clinical Pathways
News
Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer
04/14/2023
At the 2023 ESMO Gynecological Cancers Congress in Barcelona, Spain, Mansoor Raza Mirza, MD, a clinical oncologist from Rigshospitalet in Denmark, presented data on nonimmunological achievements and the role of HER2, B53, and other molecular...
At the 2023 ESMO Gynecological Cancers Congress in Barcelona, Spain, Mansoor Raza Mirza, MD, a clinical oncologist from Rigshospitalet in Denmark, presented data on nonimmunological achievements and the role of HER2, B53, and other molecular...
At the 2023 ESMO Gynecological...
04/14/2023
Journal of Clinical Pathways
News
The Effectiveness of a Ferroptosis-Related lncRNA Model Based on CFAP58-DT for Predicting Prognosis in Endometrial Cancer
03/17/2023

Grace Taylor

Grace Taylor
Aijun Qin, MD, and colleagues recently investigated the use of a prognostic ferroptosis-related long noncoding RNA (lncRNA) model based on the RNA gene CFAP58-DT for predicting the survival time of patients with endometrial cancer and to help...
Aijun Qin, MD, and colleagues recently investigated the use of a prognostic ferroptosis-related long noncoding RNA (lncRNA) model based on the RNA gene CFAP58-DT for predicting the survival time of patients with endometrial cancer and to help...
Aijun Qin, MD, and colleagues...
03/17/2023
Journal of Clinical Pathways
News
Costs Among Patients With Endometrial Cancer Receiving Postoperative Hemoglobin Level Testing Following Robotic-assisted Hysterectomy
05/18/2022

Ellen Kurek

Ellen Kurek
Findings from a recent study suggest that postoperative hemoglobin testing may be safely avoided unless starting hemoglobin is
Findings from a recent study suggest that postoperative hemoglobin testing may be safely avoided unless starting hemoglobin is
Findings from a recent study...
05/18/2022
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Conference Coverage

Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
News
Cost-Effectiveness Analysis of Immunotherapy Regimes in Upfront Treatment With Chemotherapy for Endometrial Cancer
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
Conference Coverage
Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer
04/22/2021
JCP Editors
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
...
04/22/2021
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Tony Mok, MD
Conference Coverage
Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology
William J. Gradishar, MD
Videos
HR-Positive and HER2-Negative Breast Cancer Treatment Updates
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
Natasha Leighl, MD
Conference Coverage
Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
06/01/2024
Natasha Leighl, MD
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed...
06/01/2024
Oncology
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
News
Cost-Effectiveness Analysis of Immunotherapy Regimes in Upfront Treatment With Chemotherapy for Endometrial Cancer
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
News
Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer
02/13/2024

Stephanie Holland 

Stephanie Holland 
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective...
02/13/2024
Oncology
News
Patient-Reported Quality of Life in Patients With Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab
01/17/2024

By Emry Lloyd

By Emry Lloyd
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.
Researchers have found that a...
01/17/2024
Journal of Clinical Pathways
News
Survival Benefits of Carboplatin Plus Paclitaxel and Immunotherapy in Patients With Advanced Endometrial Cancer
11/29/2023

Grace Taylor

Grace Taylor
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and...
11/29/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement